Karyopharm to Cut About 20% of Workforce Amid Ongoing Review

Dow Jones

2025/07/11

By Connor Hart

Karyopharm Therapeutics said it will further reduce its workforce by approximately 20% as part of its ongoing management of operating expenses.

The commercial-stage pharmaceutical company had 279 employees as of Feb. 14, according to the latest headcount available in filings with the Securities and Exchange Commission.

Karyopharm expects one-time expenses stemming from the layoffs to be immaterial. The company said Friday that it remains committed to expanding the use of its treatment for multiple myeloma, a type of blood cancer, as well as advancing ongoing trials for its treatments of myelofibrosis and endometrial cancer.

The company is continuing to evaluate various alternatives to extend its cash runway, and said it engaged with potential investors to discuss potential financing transactions. It is also evaluating a potential merger or sale of the company, in- or out-of-court restructurings, and other refinancings of existing debt, the company said.

Shares fell 16%, to $4.21, in premarket trading. Through Thursday's close, the stock has lost nearly two-thirds of its value in the past year.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

July 11, 2025 08:21 ET (12:21 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2550595305"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550595305\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550595305?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-11 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550595305","market":"us","top_or_hot":-1,"title":"Karyopharm to Cut About 20% of Workforce Amid Ongoing Review","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KPTI\">Karyopharm Therapeutics</a> said it will further reduce its workforce by approximately 20% as part of its ongoing management of operating expenses. \n</p>\n<p>\n  The commercial-stage pharmaceutical company had 279 employees as of Feb. 14, according to the latest headcount available in filings with the Securities and Exchange Commission. \n</p>\n<p>\n  Karyopharm expects one-time expenses stemming from the layoffs to be immaterial. The company said Friday that it remains committed to expanding the use of its treatment for multiple myeloma, a type of blood cancer, as well as advancing ongoing trials for its treatments of myelofibrosis and endometrial cancer. \n</p>\n<p>\n  The company is continuing to evaluate various alternatives to extend its cash runway, and said it engaged with potential investors to discuss potential financing transactions. It is also evaluating a potential merger or sale of the company, in- or out-of-court restructurings, and other refinancings of existing debt, the company said. \n</p>\n<p>\n  Shares fell 16%, to $4.21, in premarket trading. Through Thursday's close, the stock has lost nearly two-thirds of its value in the past year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 11, 2025 08:21 ET (12:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Karyopharm to Cut About 20% of Workforce Amid Ongoing Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKaryopharm to Cut About 20% of Workforce Amid Ongoing Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-11 20:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KPTI\">Karyopharm Therapeutics</a> said it will further reduce its workforce by approximately 20% as part of its ongoing management of operating expenses. \n</p>\n<p>\n  The commercial-stage pharmaceutical company had 279 employees as of Feb. 14, according to the latest headcount available in filings with the Securities and Exchange Commission. \n</p>\n<p>\n  Karyopharm expects one-time expenses stemming from the layoffs to be immaterial. The company said Friday that it remains committed to expanding the use of its treatment for multiple myeloma, a type of blood cancer, as well as advancing ongoing trials for its treatments of myelofibrosis and endometrial cancer. \n</p>\n<p>\n  The company is continuing to evaluate various alternatives to extend its cash runway, and said it engaged with potential investors to discuss potential financing transactions. It is also evaluating a potential merger or sale of the company, in- or out-of-court restructurings, and other refinancings of existing debt, the company said. \n</p>\n<p>\n  Shares fell 16%, to $4.21, in premarket trading. Through Thursday's close, the stock has lost nearly two-thirds of its value in the past year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 11, 2025 08:21 ET (12:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KPTI","symbol_name":"Karyopharm Therapeutics Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550595305","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550595305","pubTimestamp":1752236460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Karyopharm Therapeutics said it will further reduce its workforce by approximately 20% as part of its ongoing management of operating expenses.The commercial-stage pharmaceutical company had 279 employees as of Feb. 14, according to the latest headcount available in filings with the Securities and Exchange Commission.Karyopharm expects one-time expenses stemming from the layoffs to be immaterial. The company said Friday that it remains committed to expanding the use of its treatment for multiple myeloma, a type of blood cancer, as well as advancing ongoing trials for its treatments of myelofibrosis and endometrial cancer.The company is continuing to evaluate various alternatives to extend its cash runway, and said it engaged with potential investors to discuss potential financing transactions. It is also evaluating a potential merger or sale of the company, in- or out-of-court restructurings, and other refinancings of existing debt, the company said.Shares fell 16%, to $4.21, in premar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KPTI":"Karyopharm Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Karyopharm将在持续审查中裁员约20%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KPTI":0.9},"content_text":"By Connor Hart \n\n\n \n\n\nKaryopharm Therapeutics said it will further reduce its workforce by approximately 20% as part of its ongoing management of operating expenses. \n\n\n  The commercial-stage pharmaceutical company had 279 employees as of Feb. 14, according to the latest headcount available in filings with the Securities and Exchange Commission. \n\n\n  Karyopharm expects one-time expenses stemming from the layoffs to be immaterial. The company said Friday that it remains committed to expanding the use of its treatment for multiple myeloma, a type of blood cancer, as well as advancing ongoing trials for its treatments of myelofibrosis and endometrial cancer. \n\n\n  The company is continuing to evaluate various alternatives to extend its cash runway, and said it engaged with potential investors to discuss potential financing transactions. It is also evaluating a potential merger or sale of the company, in- or out-of-court restructurings, and other refinancings of existing debt, the company said. \n\n\n  Shares fell 16%, to $4.21, in premarket trading. Through Thursday's close, the stock has lost nearly two-thirds of its value in the past year. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 11, 2025 08:21 ET (12:21 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}